TG Therapeutics, Inc.
TGTXNASDAQHealthcare● Active
$41.22
+$1.06(+2.64%)
Market Cap$6.3B
P/E Ratio—
52W High$44.65
52W Low$25.28
TG Therapeutics, Inc. (TGTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TGTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.17
Est. $0.23 · -26.1%
Revenue
$0.20B
Est. $0.20B · +2.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
TGTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | $0.42 | — | — | — | $0.23B | — |
| ▼ Q2 FY2026 | May 6, 2026 | $0.23 | $0.17 | -26.1% | $0.20B | $0.20B | +2.3% |
| ▼ Q1 FY2026 | Feb 26, 2026 | $0.35 | $0.14 | -60.0% | $0.19B | $0.19B | +0.4% |
| ▲ Q4 FY2025 | Nov 3, 2025 | $0.24 | $2.43 | +912.5% | $0.16B | $0.19B | -16.6% |
| ▼ Q3 FY2025 | Aug 4, 2025 | $0.32 | $0.17 | -46.9% | $0.14B | $0.15B | -3.5% |
| ▼ Q2 FY2025 | May 5, 2025 | $0.18 | $0.03 | -83.3% | $0.12B | $0.13B | -9.9% |
| ▲ Q1 FY2025 | Mar 3, 2025 | $0.08 | $0.15 | +87.5% | $0.11B | $0.11B | -0.6% |
| ▼ Q4 FY2024 | Nov 4, 2024 | $0.03 | $0.02 | -33.3% | $0.08B | $0.10B | -15.1% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
$0.42
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
$0.17
EPS Est.
$0.23
EPS Surpr.
-26.1%
Revenue
$0.20B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
$0.14
EPS Est.
$0.35
EPS Surpr.
-60.0%
Revenue
$0.19B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
$2.43
EPS Est.
$0.24
EPS Surpr.
+912.5%
Revenue
$0.16B
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
$0.17
EPS Est.
$0.32
EPS Surpr.
-46.9%
Revenue
$0.14B
Q2 FY2025
May 5, 2025Miss
EPS Actual
$0.03
EPS Est.
$0.18
EPS Surpr.
-83.3%
Revenue
$0.12B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.08
EPS Surpr.
+87.5%
Revenue
$0.11B
Q4 FY2024
Nov 4, 2024Miss
EPS Actual
$0.02
EPS Est.
$0.03
EPS Surpr.
-33.3%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.67 | $0.69 | $0.71 | 2 |
| Q3 FY2027 | $0.74 | $0.76 | $0.78 | 1 |
| Q2 FY2027 | $0.65 | $0.67 | $0.69 | 1 |
| Q1 FY2027 | $0.51 | $0.52 | $0.54 | 2 |
| Q4 FY2026 | $0.47 | $0.48 | $0.50 | 2 |
| Q3 FY2026 | $0.27 | $0.38 | $0.44 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.4B | $0.4B | 2 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -26.1% | $36.10 | $41.97 | +16.26% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -60.0% | $29.66 | $30.90 | +4.18% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +912.5% | $34.78 | $33.69 | -3.13% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -46.9% | $35.02 | $28.72 | -17.99% |
| ▼ Q2 FY2025 | May 5, 2025 | -83.3% | $43.44 | $37.68 | -13.26% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +87.5% | $30.09 | $34.42 | +14.39% |
| ▼ Q4 FY2024 | Nov 4, 2024 | -33.3% | $26.90 | $24.36 | -9.44% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +180.0% | $17.21 | $20.58 | +19.58% |
Q2 FY2026+16.26%
Report Date
May 6, 2026
EPS Beat/Miss
-26.1%
Price Before
$36.10
Price After
$41.97
Q1 FY2026+4.18%
Report Date
Feb 26, 2026
EPS Beat/Miss
-60.0%
Price Before
$29.66
Price After
$30.90
Q4 FY2025-3.13%
Report Date
Nov 3, 2025
EPS Beat/Miss
+912.5%
Price Before
$34.78
Price After
$33.69
Q3 FY2025-17.99%
Report Date
Aug 4, 2025
EPS Beat/Miss
-46.9%
Price Before
$35.02
Price After
$28.72
Q2 FY2025-13.26%
Report Date
May 5, 2025
EPS Beat/Miss
-83.3%
Price Before
$43.44
Price After
$37.68
Q1 FY2025+14.39%
Report Date
Mar 3, 2025
EPS Beat/Miss
+87.5%
Price Before
$30.09
Price After
$34.42
Q4 FY2024-9.44%
Report Date
Nov 4, 2024
EPS Beat/Miss
-33.3%
Price Before
$26.90
Price After
$24.36
Q3 FY2024+19.58%
Report Date
Aug 6, 2024
EPS Beat/Miss
+180.0%
Price Before
$17.21
Price After
$20.58
Avg Beat Reaction+10.28%
Avg Miss Reaction-4.05%
Beat Rate3 / 8 quarters
Largest Move+19.58% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TGTX ends December
TG Therapeutics, Inc. (TGTX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.17 — missing the analyst consensus of $0.23 by -26.1%. The next TGTX earnings date is expected around September 1, 2026.
Each quarter, investors track TGTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TGTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TGTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TGTX earnings · 5 questionsTG Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. TGTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TGTX historically reports after market close (AMC).
TGTX earnings datewhen is TGTX earningsTGTX next earnings datewhen does TGTX report earningsTGTX earnings calendar
▸ Source: FMP · TG Therapeutics, Inc. SEC filings · US GAAP · TG Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026